^
Association details:
| Biomarker: | STK11 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | PD-L1 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
123P - Impact of the STK11 mutation on the response to immunotherapy
Published date:
03/17/2021
Excerpt:
...OS was observed in the STK11mut/KRASmut population with an OS of 6.9 months, compared to 8.3 months in the STK11mut population and 33.9 months in the KRASmut population (CI95: 7.9–33.9/p = 0.018). These results are only significant between the KRASmut and KRASmut/STK11mut groups (p = 0.017).
Secondary therapy:
Chemotherapy
Source:
Title:
The association between STK11/LKB1 and/or KEAP1 mutations and response to PD-1/PD-L1 inhibitors in patients with advanced non-small cell lung cancer (NSCLC).
Published date:
05/13/2020
Excerpt:
Retrospective clinical databases from Indiana University and Karmanos Cancer Institute were queried to identify patients from 2008-2019 with advanced NSCLC treated with PD-1/PD-L1 monotherapy (group A) or concurrent chemotherapy + PD-1/PD-L1 inhibitors (group B)...Nearly ½ of patients with STK11/LKB1 and/or KEAP1 mutations achieve at least SD with PD-1/PD-L1 inhibitor monotherapy and more than 50% of those with non-PD maintain that response status for > 6 mos.
DOI:
10.1200/JCO.2020.38.15_suppl.e21538
